Array BioPharma to be acquired by drug giant Pfizer for $11.4B

Array BioPharma to be acquired by drug giant Pfizer for $11.4B

BOULDER -- Drug manufacturing giantPfizer and Array BioPharma today announced they have entered into a definitive merger agreement under which Pfizer will acquire Array, a Boulder-based... Read More

Monday June 17, 2019 Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer

Array BioPharma drugs recommended by National Comprehensive Cancer Network for CR care

Array BioPharma drugs recommended by National Comprehensive Cancer Network for CR care

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the National Comprehensive Cancer Network(NCCN) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to... Read More

Tuesday March 19, 2019 Tags: Boulder, Array BioPharma, Ron Squarer

European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

European Commission approves Array's encorafenib and binimetinib combo for melanoma treatment

BOULDER -- Array BioPharma Inc . (NASDAQ: ARRY) today announced the European Commission (EC) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of... Read More

Friday September 21, 2018 Tags: Denver, Array BioPharma, Ron Squarer, encorafenib, binimetinib

Array BioPharma names Carrie S. Cox chair of its board of directors

Array BioPharma names Carrie S. Cox chair of its board of directors

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More

Tuesday August 14, 2018 Tags: Boulder, Array BioPharma, Carrie Cox, Ron Squarer

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More

Monday July 30, 2018 Tags: Boulder, Array BioPharma, Ron Squarer

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma to collaborate with Pfizer on clinical drug trials

Array BioPharma to collaborate with Pfizer on clinical drug trials

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel... Read More

Tuesday December 19, 2017 Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer